The danger of a T-cell engager is that it works everywhere, including healthy tissue. US11242390B2 - "Protease-activated T cell bispecific molecules," issued February 8, 2022 to Hoffmann-La Roche Inc. - claims an answer: a bispecific that stays switched off until it reaches the tumor.
The load-bearing limitation is the conditional-activation mechanism. The claimed molecule carries a mask that blocks its activity; a protease enriched in the tumor microenvironment cleaves that mask, unmasking the engager only where the protease is present. The binding arms (anti-CD3, anti-tumor-antigen) are conventional engager parts - the novelty is the protease-cleavable switch.
Why is the switch the invention and not the arms? Because engagers that bind CD3 and a tumor antigen are well-trodden prior art. What is new and claimable is the conditional, tumor-localized activation that narrows the toxicity window. The CPC tags reflect it: C07K 16/4208 (the cleavable/masking element) alongside the standard C07K 16/2809 (anti-CD3) and C07K 16/2863 binding components.
The claim-scope question turns on the protease-cleavable linker and the masking architecture - which protease, which cleavage site, what masking moiety. A competitor's masked bispecific infringes only if its switch falls within the claimed conditional-activation design. The binding targets are almost beside the point for infringement; the switch is everything.
For the landscape, conditional-activation grants represent the safety-engineering frontier of the bispecific estate. As engagers moved from blood cancers toward solid tumors, on-target-off-tumor toxicity became the limiting problem, and the patents that solve it - masking, protease activation, logic-gating - form a distinct and increasingly valuable sub-estate layered over the basic engager format.